XERIS BIOPHARMA HOLDINGS, INC. Income (Loss) Attributable to Parent, before Tax
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Income (Loss) Attributable to Parent, before Tax of -$31.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for the quarter ending 2026-06-30 was -$31.10M.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for the quarter ending 2026-03-31 was $2.23M.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for the quarter ending 2025-12-31 was $11.08M.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for the quarter ending 2025-09-30 was $621.00K.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for fiscal 2025 was $554.00K.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for fiscal 2024 was -$57.10M.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for fiscal 2023 was -$63.50M.
- XERIS BIOPHARMA HOLDINGS, INC. income (loss) attributable to parent, before tax for fiscal 2022 was -$96.08M.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.10M 10-Q · filed 2026-08-06 | -$28.87M 10-Q · filed 2026-08-06 | -$17.79M derived: sum of 3 quarters · filed 2026-08-06 | -$17.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.23M 10-Q · filed 2026-05-07 | $13.31M derived: sum of 2 quarters · filed 2026-05-07 | $13.94M derived: sum of 3 quarters · filed 2026-05-07 | $12.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.70M derived: sum of 2 quarters · filed 2026-03-02 | $9.77M derived: sum of 3 quarters · filed 2026-08-06 | $554.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $621.00K 10-Q · filed 2025-11-06 | -$1.31M derived: sum of 2 quarters · filed 2026-08-06 | -$10.53M 10-Q · filed 2025-11-06 | -$15.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.93M 10-Q · filed 2026-08-06 | -$11.15M 10-Q · filed 2026-08-06 | -$16.26M derived: sum of 3 quarters · filed 2026-08-06 | -$35.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.22M 10-Q · filed 2026-05-07 | -$14.33M derived: sum of 2 quarters · filed 2026-05-07 | -$33.40M derived: sum of 3 quarters · filed 2026-05-07 | -$47.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$24.18M derived: sum of 2 quarters · filed 2026-03-02 | -$38.43M derived: sum of 3 quarters · filed 2026-03-02 | -$57.10M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$19.06M 10-Q · filed 2025-11-06 | -$33.32M derived: sum of 2 quarters · filed 2025-11-06 | -$51.99M 10-Q · filed 2025-11-06 | -$65.62M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$14.26M 10-Q · filed 2025-08-07 | -$32.93M 10-Q · filed 2025-08-07 | -$46.55M derived: sum of 3 quarters · filed 2026-03-02 | -$59.08M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$18.67M 10-Q · filed 2025-05-08 | -$32.30M derived: sum of 2 quarters · filed 2026-03-02 | -$44.83M derived: sum of 3 quarters · filed 2026-03-02 | -$65.34M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$26.15M derived: sum of 2 quarters · filed 2026-03-02 | -$46.67M derived: sum of 3 quarters · filed 2026-03-02 | -$63.50M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$12.53M 10-Q · filed 2024-11-08 | -$33.04M derived: sum of 2 quarters · filed 2024-11-08 | -$49.88M 10-Q · filed 2024-11-08 | -$63.15M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$20.52M 10-Q · filed 2024-08-08 | -$37.35M 10-Q · filed 2024-08-08 | -$50.62M derived: sum of 3 quarters · filed 2025-03-06 | -$72.79M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$16.83M 10-Q · filed 2024-05-09 | -$30.10M derived: sum of 2 quarters · filed 2025-03-06 | -$52.27M derived: sum of 3 quarters · filed 2025-03-06 | -$78.80M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$13.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$35.44M derived: sum of 2 quarters · filed 2025-03-06 | -$61.96M derived: sum of 3 quarters · filed 2025-03-06 | -$96.08M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$22.17M 10-Q · filed 2023-11-09 | -$48.69M derived: sum of 2 quarters · filed 2023-11-09 | -$82.82M 10-Q · filed 2023-11-09 | -$133.61M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$26.52M 10-Q · filed 2023-08-08 | -$60.65M 10-Q · filed 2023-08-08 | -$111.44M derived: sum of 3 quarters · filed 2024-03-06 | -$137.44M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$34.12M 10-Q · filed 2023-05-09 | -$84.91M derived: sum of 2 quarters · filed 2024-03-06 | -$110.92M derived: sum of 3 quarters · filed 2024-03-06 | -$138.44M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$50.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$76.80M derived: sum of 2 quarters · filed 2024-03-06 | -$104.31M derived: sum of 3 quarters · filed 2024-03-06 | -$122.72M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$26.01M 10-Q · filed 2022-11-09 | -$53.52M derived: sum of 2 quarters · filed 2022-11-09 | -$71.94M 10-Q · filed 2022-11-09 | -$93.79M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$27.52M 10-Q · filed 2022-08-10 | -$45.93M 10-Q · filed 2022-08-10 | -$67.78M derived: sum of 3 quarters · filed 2022-08-10 | -$83.78M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$18.41M 10-Q · filed 2022-05-11 | -$40.27M derived: sum of 2 quarters · filed 2022-05-11 | -$56.27M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$21.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$37.86M derived: sum of 2 quarters · filed 2022-03-11 | -$91.25M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$16.00M 10-Q · filed 2021-11-10 | -$69.39M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |